Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load.

Frimpong M, Agbavor B, Duah MS, Loglo A, Sarpong FN, Boakye-Appiah J, Abass KM, Dongyele M, Amofa G, Tuah W, Frempong M, Amoako YA, Wansbrough-Jones M, Phillips RO.

PLoS Negl Trop Dis. 2019 Aug 26;13(8):e0007689. doi: 10.1371/journal.pntd.0007689. eCollection 2019 Aug.

2.

Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.

Amoako YA, Frimpong M, Awuah DO, Plange-Rhule G, Boakye-Yiadom E, Agbavor B, Sarpong F, Ahor H, Adu E, Danso KG, Abass MK, Asiedu K, Wansbrough-Jones M, Phillips RO.

J Med Case Rep. 2019 Jul 18;13(1):218. doi: 10.1186/s13256-019-2144-2.

3.

Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay.

Frimpong M, Ahor HS, Wahed AAE, Agbavor B, Sarpong FN, Laing K, Wansbrough-Jones M, Phillips RO.

PLoS Negl Trop Dis. 2019 Feb 1;13(2):e0007155. doi: 10.1371/journal.pntd.0007155. eCollection 2019 Feb.

4.

IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection.

Loglo AD, Frimpong M, Sarpong Duah M, Sarfo F, Sarpong FN, Agbavor B, Boakye-Appiah JK, Abass KM, Dongyele M, Frempong M, Pidot S, Wansbrough-Jones M, Stinear TP, Roupie V, Huygen K, Phillips RO.

PeerJ. 2018 Jul 31;6:e5294. doi: 10.7717/peerj.5294. eCollection 2018.

5.

Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.

Sarpong-Duah M, Frimpong M, Beissner M, Saar M, Laing K, Sarpong F, Loglo AD, Abass KM, Frempong M, Sarfo FS, Bretzel G, Wansbrough-Jones M, Phillips RO.

PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005695. doi: 10.1371/journal.pntd.0005695. eCollection 2017 Jul.

6.

High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana.

Boakye-Appiah JK, Steinmetz AR, Pupulampu P, Ofori-Yirenkyi S, Tetteh I, Frimpong M, Oppong P, Opare-Sem O, Norman BR, Stienstra Y, van der Werf TS, Wansbrough-Jones M, Bonsu F, Obeng-Baah J, Phillips RO.

Int J Mycobacteriol. 2016 Jun;5(2):226-30. doi: 10.1016/j.ijmyco.2016.02.004. Epub 2016 Mar 8.

7.

Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease.

Niang F, Sarfo FS, Frimpong M, Guenin-Macé L, Wansbrough-Jones M, Stinear T, Phillips RO, Demangel C.

Sci Rep. 2015 Dec 4;5:17693. doi: 10.1038/srep17693.

8.

Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography.

Wadagni A, Frimpong M, Phanzu DM, Ablordey A, Kacou E, Gbedevi M, Marion E, Xing Y, Babu VS, Phillips RO, Wansbrough-Jones M, Kishi Y, Asiedu K.

PLoS Negl Trop Dis. 2015 Nov 19;9(11):e0004247. doi: 10.1371/journal.pntd.0004247. eCollection 2015 Nov.

9.

Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.

Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE.

Cell Microbiol. 2016 Jan;18(1):17-29. doi: 10.1111/cmi.12547. Review.

10.

Reply to "compliance with antimicrobial therapy for buruli ulcer".

Phillips RO, Sarfo FS, Abass MK, Frimpong M, Ampadu E, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2014 Oct;58(10):6341. doi: 10.1128/AAC.03874-14. No abstract available.

11.

Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice.

Klis S, van der Werf TS, Phillips RO, Sarfo FS, Wansbrough-Jones M, Stienstra Y.

AIDS. 2014 Mar 13;28(5):797-8. doi: 10.1097/QAD.0000000000000146. No abstract available.

PMID:
24979651
12.

A severe case of Buruli ulcer disease with pleural effusions.

Sarfo FS, Thompson W, Phillips RO, Paintsil A, Abass MK, Frimpong M, Abotsi J, Asiedu K, Wansbrough-Jones MH.

PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2868. doi: 10.1371/journal.pntd.0002868. eCollection 2014 Jun. No abstract available.

13.

Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana.

Phillips RO, Frimpong M, Sarfo FS, Kretschmer B, Beissner M, Debrah A, Ampem-Amoako Y, Abass KM, Thompson W, Duah MS, Abotsi J, Adjei O, Fleischer B, Bretzel G, Wansbrough-Jones M, Jacobsen M.

Emerg Infect Dis. 2014 Jun;20(6):1000-3. doi: 10.3201/eid2006.131501.

14.

Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease.

Sarfo FS, Phillips RO, Zhang J, Abass MK, Abotsi J, Amoako YA, Adu-Sarkodie Y, Robinson C, Wansbrough-Jones MH.

BMC Infect Dis. 2014 Apr 15;14:202. doi: 10.1186/1471-2334-14-202.

15.

Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease.

Phillips RO, Sarfo FS, Landier J, Oldenburg R, Frimpong M, Wansbrough-Jones M, Abass K, Thompson W, Forson M, Fontanet A, Niang F, Demangel C.

PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2786. doi: 10.1371/journal.pntd.0002786. eCollection 2014 Apr.

16.

Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana.

Williamson H, Phillips R, Sarfo S, Wansbrough-Jones M, Small P.

PLoS One. 2014 Feb 10;9(2):e88007. doi: 10.1371/journal.pone.0088007. eCollection 2014.

17.

Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Phillips RO, Sarfo FS, Abass MK, Abotsi J, Wilson T, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2014;58(2):1161-6. doi: 10.1128/AAC.02165-13. Epub 2013 Dec 9. Erratum in: Antimicrob Agents Chemother. 2014 Apr;58(4):2488.

18.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

19.

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team.

JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936.

20.

Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.

Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, Lenormand P, Dosso M, Wansbrough-Jones M, Veyron-Churlet R, Guenin-Macé L, Demangel C.

PLoS Negl Trop Dis. 2011 Jul;5(7):e1237. doi: 10.1371/journal.pntd.0001237. Epub 2011 Jul 19.

21.

Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2010 Sep;54(9):3678-85. doi: 10.1128/AAC.00299-10. Epub 2010 Jun 21.

22.

Positive predictive value of the UK clinical case definition for H1N1/09 ('swine') influenza.

Bicanic T, Solomon AW, Karunaharan N, Chua F, Pope C, Pond M, Herman J, Loyse A, Harrison T, Wansbrough-Jones M.

J Infect. 2010 May;60(5):405-7. doi: 10.1016/j.jinf.2010.02.001. Epub 2010 Feb 7. No abstract available.

PMID:
20144897
23.

Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue.

Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, Tarelli E, Asiedu KB, Small PL, Wansbrough-Jones MH.

PLoS Negl Trop Dis. 2010 Jan 5;4(1):e577. doi: 10.1371/journal.pntd.0000577.

24.

Neglected tropical diseases.

Feasey N, Wansbrough-Jones M, Mabey DC, Solomon AW.

Br Med Bull. 2010;93:179-200. doi: 10.1093/bmb/ldp046. Epub 2009 Dec 10. Review.

PMID:
20007668
25.

Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease.

Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C.

J Infect Dis. 2009 Dec 1;200(11):1675-84. doi: 10.1086/646615.

PMID:
19863437
26.

Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer.

Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, Lartey A, Adentwe E, Opare W, Asiedu KB, Wansbrough-Jones M.

J Clin Microbiol. 2009 Apr;47(4):924-6. doi: 10.1128/JCM.01842-08. Epub 2009 Feb 9.

27.

Buruli ulcer disease: prospects for a vaccine.

Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, Johnson RC, Pedrosa J, Phanzu DM, Phillips RO, Pluschke G, Siegmund V, Singh M, van der Werf TS, Wansbrough-Jones M, Portaels F.

Med Microbiol Immunol. 2009 May;198(2):69-77. doi: 10.1007/s00430-009-0109-6. Epub 2009 Feb 7. Review.

PMID:
19198877
28.

Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M.

Clin Vaccine Immunol. 2009 Jan;16(1):61-5. doi: 10.1128/CVI.00235-08. Epub 2008 Nov 12.

29.

Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies.

Asiedu K, Wansbrough-Jones M.

Med J Aust. 2007 Jan 15;186(2):55-6. No abstract available.

PMID:
17223762
30.

Buruli ulcer: emerging from obscurity.

Wansbrough-Jones M, Phillips R.

Lancet. 2006 Jun 3;367(9525):1849-58. Review.

PMID:
16753488
31.

Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.

Phillips R, Horsfield C, Mangan J, Laing K, Etuaful S, Awuah P, Nyarko K, Osei-Sarpong F, Butcher P, Lucas S, Wansbrough-Jones M.

Infect Immun. 2006 May;74(5):2917-24.

32.

Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

Phillips R, Horsfield C, Kuijper S, Sarfo SF, Obeng-Baah J, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M.

Clin Vaccine Immunol. 2006 Feb;13(2):253-7.

33.

Acute bilateral parotitis caused by Mycobacterium scrofulaceum: immune reconstitution disease in a patient with AIDS.

Lawn SD, Checkley A, Wansbrough-Jones MH.

Sex Transm Infect. 2005 Dec;81(6):517-8. No abstract available.

34.

Mycobacterium ulcerans disease.

van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, Wansbrough-Jones MH, Johnson PD, Portaels F, van der Graaf WT, Asiedu K.

Bull World Health Organ. 2005 Oct;83(10):785-91. Epub 2005 Nov 10. Review.

35.

Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer.

Phillips R, Horsfield C, Kuijper S, Lartey A, Tetteh I, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M.

J Clin Microbiol. 2005 Aug;43(8):3650-6.

36.

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3182-6.

37.

Buruli ulcer.

Wansbrough-Jones M, Phillips R.

BMJ. 2005 Jun 18;330(7505):1402-3. No abstract available.

38.

Emerging aspects of Buruli ulcer.

Thangaraj HS, Phillips RO, Evans MR, Wansbrough-Jones MH.

Expert Rev Anti Infect Ther. 2003 Aug;1(2):217-22. Review.

PMID:
15482116
39.

In vitro killing of Mycobacterium ulcerans by acidified nitrite.

Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, Kolk AH.

Antimicrob Agents Chemother. 2004 Aug;48(8):3130-2.

40.

Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides.

Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2004 Aug;48(8):2866-70.

41.

An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease.

Evans MR, Phillips R, Etuaful SN, Amofah G, Adomako J, Adjei O, Dennis-Antwi J, Lucas SB, Wansbrough-Jones MH.

Trans R Soc Trop Med Hyg. 2003 Mar-Apr;97(2):159-60.

PMID:
14584368
42.

A black necrotic ulcer.

Lawn SD, Planche T, Riley P, Holwill S, Silman N, Bewley K, Rice P, Wansbrough-Jones MH.

Lancet. 2003 May 3;361(9368):1518. No abstract available.

PMID:
12737863
43.

Treatment of tuberculosis in HIV-infected individuals.

Harrison TS, Macallan DC, Rayner CF, Wansbrough-Jones M.

AIDS. 2002 Jul 26;16(11):1569-70; author reply 1571-2. No abstract available.

PMID:
12131203
44.

Buruli ulcer.

Evans MR, Thangaraj HS, Wansbrough-Jones MH.

Curr Opin Infect Dis. 2000 Apr;13(2):109-112.

PMID:
11964776
45.

Cervical schistosomiasis.

Sharma S, Boyle D, Wansbrough-Jones MH, Chiodini PL, Smith JR.

Int J Gynecol Cancer. 2001 Nov-Dec;11(6):491-2.

PMID:
11906555
46.

Mycobacterium ulcerans disease; Buruli ulcer.

Thangaraj HS, Evans MR, Wansbrough-Jones MH.

Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):337-40. Review. No abstract available.

PMID:
10674068
47.

In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.

Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MR, Banerjee DK, Wansbrough-Jones MH.

J Antimicrob Chemother. 2000 Feb;45(2):231-3.

PMID:
10660507
48.

Squamous cell carcinoma secondary to Buruli ulcer.

Evans MR, Etuaful SN, Amofah G, Adjei O, Lucas S, Wansbrough-Jones MH.

Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):63-4. No abstract available.

PMID:
10492793
49.

Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana.

Wansbrough-Jones MH, Frimpong E, Cant B, Harris K, Evans MR, Teo CG.

Trans R Soc Trop Med Hyg. 1998 Sep-Oct;92(5):496-9.

PMID:
9861360
50.

Pneumococcal endocarditis, pneumonia and meningitis complicated by necrosis of a limb.

Weir A, Lam D, Wansbrough-Jones M.

J R Soc Med. 1998 Aug;91(8):431-2. No abstract available.

Supplemental Content

Loading ...
Support Center